argenx Launches Tender Offer to Acquire Forte Biosciences
The Dutch immunology specialist has commenced a tender offer to acquire Forte Biosciences, expanding its clinical-stage portfolio.
argenx Moves to Acquire Forte Biosciences
Netherlands-based argenx SE (ARGX) announced Thursday morning that it has commenced a tender offer to acquire Forte Biosciences, Inc., according to a statement released before market open on August 6.
The announcement marks a strategic acquisition move for argenx, a company with a market capitalization of approximately $54 billion that specializes in immunology therapeutics. Shares closed at $748.60 in the prior session.
Transaction Details
While the company confirmed the commencement of the tender offer, specific financial terms and the offer price per share were not disclosed in the initial announcement. The tender offer process allows Forte Biosciences shareholders to tender their shares directly to argenx within a specified timeframe.
Strategic Context
The acquisition of Forte Biosciences would add clinical-stage assets to argenx's pipeline, though the companies did not elaborate on specific programs or therapeutic areas that motivated the transaction. argenx has built its reputation on developing antibody-based therapies for severe autoimmune diseases and cancer.
Upcoming Corporate Milestones
The acquisition announcement comes ahead of several key dates for argenx. According to MarginX data, the company has scheduled a Special/Extraordinary Shareholders Meeting for September 17, 2026, which may address matters related to the transaction. This meeting falls one day after the Federal Reserve's scheduled rate decision and projections release on September 16.
Later in September, argenx is slated to participate in the Muscular Dystrophy Association's 2026 MDA Engage Symposium Series in Chicago, running September 25-26. The company is expected to report third-quarter 2026 results on October 22.
Regulatory Path Forward
Tender offers typically require regulatory approval and are subject to minimum acceptance thresholds. The completion timeline and any potential regulatory hurdles were not detailed in Thursday's announcement.
This article was generated by MarginX from public news on 2026-08-06. It is not investment advice.